Molecular Imprinted Polymer Binding Capacity via Affinity Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing molecular imprinted polymers (MIPs) fail to achieve high binding capacity and specificity, making them unsuitable for clinical use as alternatives to antibodies and soluble receptors, particularly in pharmaceutical applications where target molecule clearance is relevant.
Innovation Solution
A method involving affinity purification and micronization of MIP particles to enhance their binding capacity and specificity, where MIPs are sorted based on their ability to bind a target molecule or template, and then combined with a carrier or vehicle to create a composition with improved affinity and capacity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional MIP preparation methods are used, then the process is simple and straightforward, but the binding capacity and specificity are insufficient for clinical use
Solution Approach 1:
The patent divides the MIP preparation process into distinct segments: initial polymerization, micronization to reduce particle size, and affinity purification to separate high-affinity binders from low-affinity ones. This segmentation allows each step to be optimized independently, improving overall binding capacity and specificity while making the complex process more manageable and reproducible
Solution Approach 2:
The patent employs parameter changes by optimizing particle size through micronization and selecting specific elution conditions during affinity purification. By controlling particle size distribution and using gradient elution with increasing solvent strength, the method enhances binding capacity and specificity, transforming conventional MIPs into clinically viable therapeutics
2Reliability
If MIP particles are not micronized, then the polymer structure remains intact, but the binding sites are not accessible and template removal is inefficient
Solution Approach 1:
The patent applies partial micronization rather than complete degradation of the polymer structure. By reducing particle size to a specific range (1-50 μm), the method achieves sufficient template removal efficiency and binding site accessibility while preserving the structural integrity needed for maintaining binding capacity. This partial action avoids over-processing that would destroy the polymer framework
3Reliability
If all MIP particles are used without purification, then the process is efficient, but low-affinity and non-binding particles reduce overall binding capacity
Solution Approach 1:
The patent extracts and removes low-affinity and non-binding MIP particles from the mixture through affinity purification. By using template molecules or analogs as eluents, the method selectively elutes high-affinity binders while leaving low-affinity particles in the column, thereby concentrating the active binding sites and significantly improving overall binding capacity of the final product
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly increases the binding capacity and specificity of MIPs, allowing them to be used effectively in pharmaceutical applications, such as treating cardiovascular diseases and gastrointestinal tract-related conditions, by concentrating high-affinity binding sites and optimizing particle size for enhanced performance.
Implementation Method 1
MIPs are sorted based on their ability to bind a target molecule or template
Implementation Method 2
subjecting the suspended MIPs to an affinity purification procedure, wherein the template molecule or a fragment thereof or a mimic thereof is used as capture agent
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
One aspect is a method for improved preparation of molecular imprinted polymer (MIP) particles, where initial compositions comprising insoluble MIP particles are enriched for those MIP particles that bind a particular target molecule, thus excluding non-binding and weakly binding particles from the final composition. Enrichment is typically accomplished via use of chromatographic methods capable of separating particulate material or by means of agglutination. Another aspect is preparation of improved insoluble MIPs by use of extended micronization of raw MIP particles with a view to expose a large number of binding sites per mass unit of MIP particles. In preferred embodiments the two aspects are combined. The resulting improved MIPs may be used for diagnostic, analytical and therapeutic purposes, notably as orally administered drugs which can bind substances such as cholesterol and bile acids and bile acid salts in the gastrointestinal tract.